Last updated: 29 May 2022 at 5:08am EST

John McKearn Net Worth




The estimated Net Worth of John P Mckearn is at least 101 百万$ dollars as of 26 March 2021. John Mckearn owns over 7,439 units of Allakos Inc stock worth over 732$ and over the last 10 years he sold ALLK stock worth over 100,603,191$. In addition, he makes 432,260$ as Independent Director at Allakos Inc.

John McKearn ALLK stock SEC Form 4 insiders trading

John has made over 10 trades of the Allakos Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 7,439 units of ALLK stock worth 855,485$ on 26 March 2021.

The largest trade he's ever made was selling 1,150,000 units of Allakos Inc stock on 12 May 2020 worth over 81,696,000$. On average, John trades about 110,269 units every 151 days since 2014. As of 26 March 2021 he still owns at least 1,200 units of Allakos Inc stock.

You can see the complete history of John Mckearn stock trades at the bottom of the page.





John McKearn biography

Dr. John P. McKearn Ph.D. serves as Independent Director of the Company. Dr. McKearn joined RiverVest Venture Partners, a venture capital firm, in April 2008 as a Venture Partner and has been a Managing Director since April 2011. Prior to joining RiverVest, Dr. McKearn was the Chief Executive Officer of Kalypsys, a biopharmaceutical company, from 2005 to December 2006, its President from 2004 to December 2006 and its Chief Scientific Officer from 2003 to 2005. From 2000 to June 2009, Dr. McKearn served on the board ofIDM Pharma (acquired by Takeda), a biotechnology company. He also previously served on the board of directors of Epimmune, Keel Pharmaceuticals, ZS Pharma, Otonomy and Lumena Pharmaceuticals and currently serves as a member of the board of directors of Arch Oncology, OncoResponse, Good Therapeutics and Adarza Biosystems. From 1987 to 2003, Dr. McKearn worked as a scientist with G.D. Searle & Company, which merged into Pharmacia Corporation in 2000, serving as the head of discovery research from 1997 to 2003. Before that, he was a senior scientist at E.I. DuPont de Nemours and Company, a member of the Basel Institute for Immunology in Basel, Switzerland and a research associate in the Department of Microbiology and Immunology at Washington University in St. Louis.

What is the salary of John McKearn?

As the Independent Director of Allakos Inc, the total compensation of John McKearn at Allakos Inc is 432,260$. There are 11 executives at Allakos Inc getting paid more, with Robert Alexander having the highest compensation of 12,559,300$.



What's John McKearn's mailing address?

John's mailing address filed with the SEC is C/O ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS, CA, 94070.

Insiders trading at Allakos Inc

Over the last 6 years, insiders at Allakos Inc have traded over 246,100,922$ worth of Allakos Inc stock and bought 5,181,222 units worth 35,384,176$ . The most active insiders traders include Paul Edward WalkerGroup, Llc Green Jeremy Red...Daniel Janney. On average, Allakos Inc executives and independent directors trade stock every 43 days with the average trade being worth of 114,372$. The most recent stock trade was executed by Harlan Baird Radford on 28 June 2024, trading 87,064 units of ALLK stock currently worth 87,935$.



What does Allakos Inc do?

allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.



Complete history of John Mckearn stock trades at Otonomy Inc、Allakos Inc

インサイダー
取引
取引
合計金額
John P Mckearn
ディレクター
販売 855,485$
26 Mar 2021
John P Mckearn
ディレクター
販売 81,696,000$
12 May 2020
John P Mckearn
ディレクター
販売 1,541,534$
7 Jun 2019
John P Mckearn
ディレクター
販売 3,733,465$
4 Jun 2019
John P Mckearn
ディレクター
販売 2,133,060$
30 May 2019
John P Mckearn
ディレクター
販売 3,266,323$
16 Apr 2019
John P Mckearn
ディレクター
販売 4,905,133$
15 Feb 2019
John P Mckearn
ディレクター
販売 2,252,441$
24 Jan 2019
John P Mckearn
ディレクター
購入する 1,999,998$
23 Jul 2018
John P Mckearn
ディレクター
販売 219,750$
18 Aug 2014


Allakos Inc executives and stock owners

Allakos Inc executives and other stock owners filed with the SEC include: